News & Updates

Show Multimedia Only
More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC

More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC

09 May 2024 byKanas Chan

Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide reported more fatigue, depression and deterioration in perceived cognitive ability, and slower reaction time than those receiving abiraterone acetate, according to results of the ACE study.

More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC

09 May 2024
Abdominal fat tied to reduced brain function in middle-aged men at high dementia risk

Abdominal fat tied to reduced brain function in middle-aged men at high dementia risk

07 May 2024
Detecting Alzheimer’s disease biomarkers: Timing matters

Detecting Alzheimer’s disease biomarkers: Timing matters

02 May 2024